Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee

Clinical Therapeutics

Volumn 23, Issue 2, 2001, Pages 213-227

  Williams, Gary W ^a   Hubbard, Richard C ^b   Yu, Shawn S ^b   Zhao, William ^b   Geis, G Steven ^b  

^a SCRIPPS CLINIC   (United States)

^b PFIZER INC   (United States)

Author keywords

Celecoxib; COX 2 inhibitor; Dosing regimen; Efficacy; Osteoarthritis; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0035082412     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80004-7     Document Type: Article

References (30)

1. Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis
2. Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection
3. Current issues in NSAID therapy
4. Cyclooxygenase in biology and disease
5. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
6. Prostaglandin endoperoxide H synthases- 1 and -2
7. Effects of nonsteroidal anti-inflammatory therapy on platelets
8. Future trends in the development of safer nonsteroidal anti-inflammatory drugs
9. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
10. Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration
11. Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data
12. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
13. COX-1 and COX-2 tissue expression: Implications and predictions
14. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
15. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
16. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
17. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor
18. Kinetic basis for selective inhibition of cyclo-oxygenases
19. Overview of issues related to medical compliance with implications for the out-patient management of infectious diseases
20. Improving medication adherence through patient education distinguishing between appropriate and inappropriate utilization
21. Nonsteroidal anti-inflammatory drug use in the elderly: Issues of compliance and safety
22. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee
23. Therapeutic criteria in rheumatoid arthritis
24. Indexes of severity of osteoarthritis of the hip and knee. Validation - Value in comparison with other assessment tests
25. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
26. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: A randomized, controlled trial
27. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial